CLOCK and acute myeloid leukemia: Strikingly, in contrast to non‐AML controls, the AML cohort did not display the expected progressive gain of DNAm at PRC2 targets using chronological age nor pan‐tissue epi‐clock (Figure 5A,B; Figure S8).